View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
Beam, Inc. (BEAM) Tops Q4 EPS by 18c
-
Increasing unusual option volume: GT FROG KC FITB CNR VNET ABSI BEAM
-
BMO Capital on Beam Therapeutics Inc (BEAM): 'AATD Readout in 1H25 Could Move BEAM 50-100%+'
-
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
Beam Therapeutics (BEAM) to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
-
Beam Therapeutics Inc. (BEAM) Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
-
Bernstein's top two SMID biotech picks for 2025
-
7 top biotech picks for 2025 according to Wells Fargo
-
BMO Capital Reiterates Outperform Rating on Beam Therapeutics Inc (BEAM)
-
Beam Therapeutics Inc. (BEAM) Appoints Sravan Emany as CFO
-
Beam Therapeutics (BEAM) Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
-
Leerink Partners Upgrades Beam Therapeutics Inc (BEAM) to Outperform, 'we see a far more attractive risk/reward'
-
JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)
-
Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'
-
BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'
-
Beam, Inc. (BEAM) Tops Q3 EPS by 1c
-
Jones Trading Starts Beam Therapeutics Inc (BEAM) at Hold
-
Beam Therapeutics Inc (BEAM) PT Raised to $69 at Stifel
-
Beam, Inc. (BEAM) Tops Q2 EPS by 2c
-
Beam Therapeutics Inc. (BEAM) Announces CFO Change
